In 2019, the U.S. Food and Drug Administration (FDA) approved the use of the immune checkpoint inhibitor atezolizumab, an anti-PD-L1 monoclonal antibody, in the treatment of metastatic triple-negative breast cancer patients; with the combination of atezolizumab and nab-paclitaxel significantly prolonging the survival time in these breast cancer patients 6. Here, CD274 is linked to triple-negative breast carcinoma.